Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

BackgroundThere is no standard treatment for stage III lung cancer due to its low surgical resection rate, and improving PFS and survival of patients with III NSCLC has become an urgent challenge in clinical treatment. For EGFR mutation-positive patients, targeted therapy has the remarkable feature...

Full description

Bibliographic Details
Main Authors: Shao Feng, Zhang Qiang, Cheng Wanwan, Zeng Zhaozhun, Xie Yuewu, Fang Shencun
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
aumolertinib
NSCLC
neoadjuvant
EGFR
adjuvant
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.872225/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.872225/full

Similar Items